CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31

CORCEPT THERAPEUTICS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026

$112.10+1.94 (+1.76%)

Close on Oct 19, 2026

Market cap: $13.27B
P/E (TTM): 266.9
Dividend yield: –

CORCEPT THERAPEUTICS INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31	FY 2006 2006-12-31
Revenue	761	675	482	402	366	354	306	251	159	81	50	27	10	3.31	–	–	0.03	–	–	–
Cost of Revenue	13	11	6.48	5.39	5.28	5.58	5.50	5.22	3.55	2.06	1.36	0.88	0.14	0.09	–	–	–	–	–	–
Gross Profit	748	664	476	396	361	348	301	246	156	79	49	26	10	3.22	–	–	–	–	–	–
Research & Development	255	247	184	131	114	115	89	75	40	24	15	18	20	14	21	19	14	–	–	–
Selling, General & Admin	449	280	184	153	122	105	100	81	62	45	37	35	31	25	11	8.49	–	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	–	–	–	–	–	–	11	8.49	5.88	–	–	–
Operating Expenses	–	–	–	–	–	–	–	–	–	–	–	54	52	40	32	27	20	–	–	–
Total Costs & Expenses	717	538	375	289	242	226	195	162	106	71	54	54	52	–	–	–	–	–	–	–
Operating Income	45	137	107	113	124	128	112	89	53	10	-3.44	-28	-41	-36	-32	-27	-20	–	–	–
Interest Expense	–	–	–	–	–	–	–	–	–	–	–	–	–	1.70	–	–	–	–	–	–
Other Non-Operating Income	22	25	17	3.56	0.53	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Legal Settlements	–	0	0	-14	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Pretax Income	66	161	125	116	125	132	117	92	53	8.14	-6.41	–	–	–	–	–	–	–	–	–
Income Tax Expense	-33	20	18	15	12	26	22	17	-76	0	0	0	–	–	–	–	–	–	–	–
Net Income	100	141	106	101	113	106	94	75	129	8.14	-6.41	-31	-46	-38	-32	-26	-20	-20	-12	-25
Net Income to Common	98	140	105	101	113	106	–	–	–	–	–	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	0.95	1.35	1.02	0.95	0.97	0.92	0.82	0.65	1.14	0.07	-0.06	-0.31	-0.46	-0.41	-0.39	-0.38	-0.38	–	–	–
EPS (Diluted)(per share)	0.82	1.23	0.94	0.87	0.89	0.85	0.77	0.60	1.04	0.07	-0.06	-0.31	-0.46	-0.41	-0.39	-0.38	-0.38	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	104	103	104	107	116	115	114	115	114	111	107	101	100	93	83	68	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	120	113	112	116	126	124	123	127	125	116	107	101	100	93	83	68	–	–	–	–
Dividend per Share(per share)	–	–	–	–	–	–	–	–	–	–	–	–	0.00	–	–	–	–	–	–	–
EBITDA	46	138	108	114	126	129	112	90	53	10	-3.29	-27	-41	-36	-32	-27	-20	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 98.3%
Operating margin: 0.8%
Net margin: 6.6%
Return on equity, FY2025: 15.0%

Financial strength

Current ratio: 2.86
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 72.2%

Valuation

P/E ratio: 266.9
Price to sales: 15.97
Price to book: 18.80
Dividend yield: –